Biogen Inc. SEC filings BIIB
Biogen Inc. has 1,001 filings in SEC EDGAR's recent list, going back to Oct 2, 2014. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Oct 28, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Oct 28, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 28, 2026 | — |
| DEF 14A | Proxy statement | Apr 28, 2026 | Jun 9, 2026 |
| DEFA14A | Additional proxy material | Jun 2, 2025 | — |
| DEFA14A | Additional proxy material | Apr 28, 2025 | — |
| DEF 14A | Proxy statement | Apr 28, 2025 | Jun 17, 2025 |
| DEFA14A | Additional proxy material | Apr 26, 2024 | — |
| DEF 14A | Proxy statement | Apr 26, 2024 | Jun 20, 2024 |
| PRE 14A | Preliminary proxy statement | Apr 12, 2024 | Jun 20, 2024 |
| DEFA14A | Additional proxy material | Jul 31, 2023 | — |
| DEFA14A | Additional proxy material | Jul 28, 2023 | — |
| DEFA14A | Additional proxy material | Jun 13, 2023 | — |
| DEFA14A | Additional proxy material | Jun 12, 2023 | — |
| DEFA14A | Additional proxy material | Apr 28, 2023 | — |
| DEF 14A | Proxy statement | Apr 28, 2023 | — |
| DEFA14A | Additional proxy material | Jun 7, 2022 | — |
| DEFA14A | Additional proxy material | Apr 29, 2022 | — |
| DEF 14A | Proxy statement | Apr 29, 2022 | Jun 15, 2022 |
| DEFA14A | Additional proxy material | Apr 23, 2021 | — |
| DEF 14A | Proxy statement | Apr 23, 2021 | Jun 2, 2021 |
| PRE 14A | Preliminary proxy statement | Apr 9, 2021 | Jun 2, 2021 |
| DEFA14A | Additional proxy material | Apr 9, 2021 | — |
| DEFA14A | Additional proxy material | Apr 20, 2020 | — |
| DEF 14A | Proxy statement | Apr 20, 2020 | Jun 3, 2020 |
| DEFA14A | Additional proxy material | May 24, 2019 | — |
| DEFA14A | Additional proxy material | Apr 30, 2019 | — |
| DEF 14A | Proxy statement | Apr 30, 2019 | Jun 19, 2019 |
| DEFA14A | Additional proxy material | Apr 29, 2019 | — |
| DEFA14A | Additional proxy material | Apr 27, 2018 | — |
| DEF 14A | Proxy statement | Apr 27, 2018 | Jun 12, 2018 |
| DEFA14A | Additional proxy material | Apr 26, 2017 | — |
| DEF 14A | Proxy statement | Apr 26, 2017 | Jun 7, 2017 |
| DEFA14A | Additional proxy material | Apr 15, 2016 | — |
| DEF 14A | Proxy statement | Apr 15, 2016 | Jun 8, 2016 |
| DEFA14A | Additional proxy material | Apr 30, 2015 | — |
| DEF 14A | Proxy statement | Apr 30, 2015 | Jun 10, 2015 |
Showing 35 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- BIIB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 875045
- Former names
- BIOGEN IDEC INC. (until Mar 20, 2015); BIOGEN IDEC INC (until Apr 25, 2007); IDEC PHARMACEUTICALS CORP / DE (until Nov 12, 2003); IDEC PHARMACEUTICALS CORP / CA (until Feb 14, 1997)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
- Neurocrine Biosciences Inc NBIX
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.